Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: The malmö diet and cancer study

Journal of the American College of Cardiology

Volumn 64, Issue 14, 2014, Pages 1452-1460

  Hallengren, Erik ^a,b   Almgren, Peter ^a   Engström, Gunnar ^a   Hedblad, Bo ^a,b   Persson, Margaretha ^a,b   Suhr, Jennifer ^c   Bergmann, Andreas ^d,e   Melander, Olle ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c ICI immunochemical intelligence GmbH   (Germany)

^d SPHINGOTEC GMBH   (Germany)

^e Hohen Neuendorf   (Germany)

Author keywords

cardiovascular disease; epidemiology; growth hormone; mortality

Indexed keywords

ANTIHYPERTENSIVE AGENT; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; HUMAN GROWTH HORMONE;

ADULT; AGED; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CRITICALLY ILL PATIENT; DRUG MEGADOSE; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INCIDENCE; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MOUSE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PREVALENCE; PROSPECTIVE STUDY; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; BLOOD; CARDIOVASCULAR DISEASE; DIET; DIET RESTRICTION; HEART FAILURE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STROKE; SWEDEN; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DIET; FASTING; FEMALE; HEART FAILURE; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE; SWEDEN; TREATMENT OUTCOME;

EID: 84908130142     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.03.063     Document Type: Article

References (42)

1. N. Møller, and J.O. Jørgensen Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects Endocr Rev 30 2009 152 177
2. T. Rosen, and B.A. Bengtsson Premature mortality due to cardiovascular disease in hypopituitarism Lancet 336 1990 285 288
3. J. Svensson, B.A. Bengtsson, and T. Rosen Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy J Clin Endocrinol Metab 89 2004 3306 3312
4. B. Bulow, L. Hagmar, and Z. Mikoczy Increased cerebrovascular mortality in patients with hypopituitarism Clin Endocrinol (Oxf) 46 1997 75 81
5. J.W. Tomlinson, N. Holden, R.K. Hills West Midlands Prospective Hypopituitary Study Group Association between premature mortality and hypopituitarism Lancet 357 2001 425 431
6. R. Abs, U. Feldt-Rasmussen, and A.F. Mattsson Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis Eur J Endocrinol 155 2006 79 90
7. B. Bulow, L. Hagmar, and J. Eskilsson Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors J Clin Endocrinol Metab 85 2000 574 584
8. G. Sesmilo, B.M. Biller, and J. Llevadot Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial Ann Intern Med 133 2000 111 122
9. C. Beauregard, A.L. Utz, and A.E. Schaub Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study J Clin Endocrinol Metab 93 2008 2063 2071
10. P. Maison, S. Griffin, M. Nicoue-Beglah Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials J Clin Endocrinol Metab 89 2004 2192 2199
11. S.M. Orme, R.J. McNally, R.A. Cartwright United Kingdom Acromegaly Study Group Mortality and cancer incidence in acromegaly: a retrospective cohort study J Clin Endocrinol Metab 83 1998 2730 2734
12. S. Melmed, F.F. Casanueva, and A. Klibanski A consensus on the diagnosis and treatment of acromegaly complications Pituitary 10 2013 243 248
13. A. Colao, P. Marzullo, and C. Di Somma Growth hormone and the heart Clin Endocrinol (Oxf) 54 2001 137 154
14. J. Takala, E. Ruokonen, and N.R. Webster Increased mortality associated with growth hormone treatment in critically ill adults New Engl J Med 341 1999 785 792
15. P. Maison, B. Balkau, and D. Simon Growth hormone as a risk for premature mortality in healthy subjects: data from the Paris prospective study BMJ 316 1998 1132 1133
16. S. Saini, P.C. Hindmarsh, and D.R. Matthews Reproducibility of 24-hour serum growth hormone profiles in man Clin Endocrinol (Oxf) 34 1991 455 462
17. S. Surya, K. Symons, and E. Rothman Complex rhythmicity of growth hormone secretion in humans Pituitary 9 2006 121 125
18. C.A. Jaffe, B. Ocampo-Lim, and W. Guo Regulatory mechanisms of growth hormone secretion are sexually dimorphic J Clin Invest 102 1998 153 164
19. M. Bidlingmaier, J. Suhr, and A. Ernst High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports Clin Chem 55 2009 445 453
20. G. Berglund, S. Elmstahl, and L. Janzon The Malmo Diet and Cancer Study. Design and feasibility J Intern Med 233 1993 45 51
21. M. Rosvall, L. Janzon, and G. Berglund Incidence of stroke is related to carotid IMT even in the absence of plaque Atherosclerosis 179 2005 325 331
22. F. Di Serio, V. Ruggieri, and L. Varraso Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010 Clin Chem Lab Med 43 2005 1263 1273
23. P. Jerntorp, and G. Berglund Stroke registry in Malmö, Sweden Stroke 23 1992 357 361
24. N. Hammar, L. Alfredsson, and M. Rosén A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden Int J Epidemiol 30 Suppl 1 2001 S30 S34
25. G. Sarno, B. Lagerqvist, and J. Carlsson Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Int J Cardiol 167 2013 146 150
26. E. Ingelsson, J. Ärnlöv, and J. Sundström The validity of a diagnosis of heart failure in a hospital discharge register Eur J Heart Fail 7 2005 787 791
27. R.B. D'Agostino Sr., R.S. Vasan, and M.J. Pencina General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 2008 743 753
28. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21
29. M.J. Pencina, and R.B. D'Agostino Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation Stat Med 23 2004 2109 2123
30. H. Liu, D.M. Bravata, and I. Olkin Systematic review: the safety and efficacy of growth hormone in the healthy elderly Ann Int Med 146 2007 104 115
31. V. Birzniece, A.E. Nelson, and K.K. Ho Growth hormone and physical performance Trends Endocrinol Metab 22 2011 171 178
32. L. Wideman, J.Y. Weltman, and M.L. Hartman Growth hormone release during acute and chronic aerobic and resistance exercise: recent findings Sports Med 32 2002 987 1004
33. A. Bartke Can growth hormone (GH) accelerate aging? Evidence from GH-transgenic mice Neuroendocrinology 78 2003 210 216
34. K.T. Coschigano, A.N. Holland, and M.E. Riders Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span Endocrinology 144 2003 3799 3810
35. H.M. Brown-Borg, K.E. Borg, and C.J. Meliska Dwarf mice and the ageing process Nature 384 1996 33
36. M.M. Masternak, A. Bartke, and F. Wang Metabolic effects of intra-abdominal fat in GHRKO mice Aging Cell 11 2012 73 81
37. D.E. Berryman, E.O. List, and K.T. Coschigano Comparing adiposity profiles in three mouse models with altered GH signaling Growth Horm IGF Res 14 2004 309 318
38. B. Eden Engstrom, F.A. Karlsson, and T. Naessen Ambulatory morning growth hormone concentrations increase in men and decrease in women with age Scand J Clin Lab Invest 62 2002 25 31
39. S.M. Pincus, E.F. Gevers, and I.C. Robinson Females secrete growth hormone with more process irregularity than males in both humans and rats Am J Physiol 270 1996 E107 E115
40. P.C. Hindmarsh, E. Dennison, and S.M. Pincus A sexually dimorphic pattern of growth hormone secretion in the elderly J Clin Endocrinol Metab 84 1999 2679 2685
41. J.D. Veldhuis, F. Roelfsema, and D.M. Keenan Gender, age, body mass index, and IGF-I individually and jointly determine distinct GH dynamics: analyses in one hundred healthy adults J Clin Endocrinol Metab 96 2011 115 121
42. K.Y. Ho, W.S. Evans, and R.M. Blizzard Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations J Clin Endocrinol Metab 64 1987 51 58